Chromosome instability and benefit from adjuvant anthracyclines in breast cancer

BACKGROUND: Duplication of the centromeric region of chromosome 17 (Ch17CEP) is associated with sensitivity to anthracyclines. An explanation may be chromosome instability (CIN); a frequent event in solid tumours associated with poor outcome. The predictive value of CIN seems to be drug dependent an...

Descripción completa

Detalles Bibliográficos
Autores principales: Munro, A F, Twelves, C, Thomas, J S, Cameron, D A, Bartlett, J MS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389422/
https://www.ncbi.nlm.nih.gov/pubmed/22644297
http://dx.doi.org/10.1038/bjc.2012.232
_version_ 1782237309655056384
author Munro, A F
Twelves, C
Thomas, J S
Cameron, D A
Bartlett, J MS
author_facet Munro, A F
Twelves, C
Thomas, J S
Cameron, D A
Bartlett, J MS
author_sort Munro, A F
collection PubMed
description BACKGROUND: Duplication of the centromeric region of chromosome 17 (Ch17CEP) is associated with sensitivity to anthracyclines. An explanation may be chromosome instability (CIN); a frequent event in solid tumours associated with poor outcome. The predictive value of CIN seems to be drug dependent and CIN has been associated with both sensitivity and resistance to chemotherapy. METHODS: In this study, we used fluorescent in situ hybridisation for chromosomes 1, 7, 11, 17 and 18 to identify patients with high tumour CIN% in 322 patients recruited into the BR9601 clinical trial. RESULTS: High tumour CIN% was correlated to Ch17CEP (P=3.68e−7) and is associated with a reduced RFS (P=0.0011) and OS (P=0.04). Patients with high CIN had a decreased risk of death on E-CMF compared with CMF. CONCLUSION: CIN is of prognostic significance and may be of predictive value in determining anthracycline response, although further testing is required.
format Online
Article
Text
id pubmed-3389422
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-33894222013-06-26 Chromosome instability and benefit from adjuvant anthracyclines in breast cancer Munro, A F Twelves, C Thomas, J S Cameron, D A Bartlett, J MS Br J Cancer Short Communication BACKGROUND: Duplication of the centromeric region of chromosome 17 (Ch17CEP) is associated with sensitivity to anthracyclines. An explanation may be chromosome instability (CIN); a frequent event in solid tumours associated with poor outcome. The predictive value of CIN seems to be drug dependent and CIN has been associated with both sensitivity and resistance to chemotherapy. METHODS: In this study, we used fluorescent in situ hybridisation for chromosomes 1, 7, 11, 17 and 18 to identify patients with high tumour CIN% in 322 patients recruited into the BR9601 clinical trial. RESULTS: High tumour CIN% was correlated to Ch17CEP (P=3.68e−7) and is associated with a reduced RFS (P=0.0011) and OS (P=0.04). Patients with high CIN had a decreased risk of death on E-CMF compared with CMF. CONCLUSION: CIN is of prognostic significance and may be of predictive value in determining anthracycline response, although further testing is required. Nature Publishing Group 2012-06-26 2012-05-29 /pmc/articles/PMC3389422/ /pubmed/22644297 http://dx.doi.org/10.1038/bjc.2012.232 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Munro, A F
Twelves, C
Thomas, J S
Cameron, D A
Bartlett, J MS
Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
title Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
title_full Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
title_fullStr Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
title_full_unstemmed Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
title_short Chromosome instability and benefit from adjuvant anthracyclines in breast cancer
title_sort chromosome instability and benefit from adjuvant anthracyclines in breast cancer
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389422/
https://www.ncbi.nlm.nih.gov/pubmed/22644297
http://dx.doi.org/10.1038/bjc.2012.232
work_keys_str_mv AT munroaf chromosomeinstabilityandbenefitfromadjuvantanthracyclinesinbreastcancer
AT twelvesc chromosomeinstabilityandbenefitfromadjuvantanthracyclinesinbreastcancer
AT thomasjs chromosomeinstabilityandbenefitfromadjuvantanthracyclinesinbreastcancer
AT cameronda chromosomeinstabilityandbenefitfromadjuvantanthracyclinesinbreastcancer
AT bartlettjms chromosomeinstabilityandbenefitfromadjuvantanthracyclinesinbreastcancer

Ejemplares similares